Trouble reading this e-mail? View it in your browser.

EFPIA
Newsletter
19 January 2017
Header
Header image
News

News

Statement from EFPIA President Joe Jimenez on the upcoming OECD Health Ministerial
16 January 2017

On January 17, Health Ministers from OECD countries will gather in Paris, France, to discuss how healthcare systems can reform to better deal with the [...] Read more

News

EFPIA – IFPMA Statement in response to the OECD Health Committee Ministerial Statement
17 January 2017

We welcome the Ministerial Statement from the OECD Health Committee, which seeks to address many important issues for health systems in OECD countries.  Reducing waste [...] Read more

News

The Value of the Pharmaceutical Industry; key to Europe’s economy
16 January 2017

The pharmaceutical industry continues to be a key driver of growth in the European economy. This is just one of the principle conclusions drawn by [...] Read more

Videos

Video

Powering Growth in Europe

For every Euro of direct value added by the pharmaceutical industry, more than 1.3 additional Euros are generated for the whole European economy.

View video

Video

Investing in Innovation

Pharmaceutical companies are investing 6x more in R&D than the EU’s 2020 R&D intensity target of 3%.

View video

Video

Driving Employment

Throughout the labour market, 5 European jobs are supported for each role created by the pharmaceutical industry.

View video

Events calendar

Events Calendar

DIA BioVenture Day
On 28/03/2017 (Glasgow, UK)

DIA is excited to convene its 1st BioVenture Day, in a unique format with the participation of a very broad set of senior healthcare stakeholders. You will be able to explore whether the current BioVenture paradigm is delivering returns for patients, investors, and the healthcare system.

Read more

Events Calendar

DIA EuroMeeting 2017
From 29/03/2017 to 31/03/2017 (Glasgow, UK)

The DIA EuroMeeting 2017 is unique in presenting the entire healthcare microcosm, ranging from policy and regulations, to R&D marketing and access.

In an intense and stimulating three days, you will enjoy learning and debating. You will meet not only people you know, but also those that you want to know and those that you should know.

The DIA EuroMeeting allows you to debate the issues across the entire drug development value chain during the conference, and find solutions within the exhibition with 2,500+ other cross-functional thought leaders.

You will hear the latest solutions and challenges in healthcare. You will have plenty of opportunities to network and build relationships with trend-setters in e.g. the areas of regulatory science, clinical research and operations, value demonstration leads and patient advocates. The resulting knowledge transfer and lasting partnerships will reduce the burden of regulatory barriers, benefiting your business now and further down the line.

Read more

Documents

From our blog

The Economic Footprint of Selected Pharmaceutical Companies in Europe
16 January 2017 (Publications)

This research study, conducted by the independent economic research institute WifOR, investigates the direct economic impact of selected companies of the pharmaceutical industry in Europe [...] Read more

What we are reading

What we are reading

‘It was a really fantastic experience’ – an interview with the MARCAR project coordinator
19 January 2017 (IMI)

Cancer risk assessment is one of the most important steps during the development of new medicines. Launched in 2010, IMI’s MARCAR project aimed to develop early biological clues – biomarkers – which could help predict which drugs might lead to tumour growth. At the end of the project, MARCAR project coordinator, Jonathan Moggs of Novartis, spoke to the IMI programme office about the main project achievements and explained how MARCAR project outputs will make drugs safer in the future.

Read more

What we are reading

Ministerial Statement: The next generation of health reforms - OECD Health Ministerial Meeting
19 January 2017 (OECD)

Health Ministers and Representatives of OECD Members and Argentina, Colombia, Costa Rica, Kazakhstan, Lithuania, Peru and South Africa met in Paris on 17 January 2017 to share views and options on how to design and implement the Next Generation of Health Reforms. 

Read more

What we are reading

‘We took the lead over US-based projects’ – an interview with SUMMIT project coordinators
19 January 2017 (IMI)

Before SUMMIT started in 2009, ongoing research on diabetic complications in Europe was scattered amongst various countries. Fast forward six years, and Europe – by joining forces and activities - has climbed to the top of the research ladder in this field, coming close to or even surpassing similar research projects in the US. In an interview with the IMI project office, SUMMIT project coordinator Michael Mark of Boehringer-Ingelheim, and scientific coordinator Leif Groop of Lund University, explain how SUMMIT contributed to the diabetes complications field.

Read more

What we are reading

Antonio Tajani elected new President of the European Parliament
19 January 2017 (European Parliament)

Antonio Tajani (EPP, IT) won Parliament’s presidential election with 351 votes in a final face-off with Gianni Pittella (S&D, IT), who secured 282 votes. 

Read more

About EFPIA updates
Unsubscribe to be removed from this mailing list | Update your subscription

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 34 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.
Leopold Plaza Building
Rue du Trône 108
B-1050 Brussels (Belgium)
Tel: +32 (0)2 626 25 55
E-mail: communications@efpia.eu
Follow EFPIA
Twitter LinkedIn Youtube Google + Pinterest E-mail